GlaxoSmithKline News and Research

RSS

Novel drug shows promise for MLL leukemia

According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

GAVI to purchase $1 billion in childhood vaccines for distribution in 37 of the poorest nations

The Geneva-based GAVI Alliance, a fund backed by governments, the World Bank, the WHO and the Bill & Melinda Gates Foundation, said in an e-mailed statement on Tuesday that it will purchase more than $1 billion in vaccines against rotavirus, pneumococcal and other diseases through deals made with GlaxoSmithKline, Pfizer Inc. and Merck & Co. to immunize children in 37 of the poorest nations, Bloomberg reports.

28 Sep 2011

Whooping cough vaccine may lose protective capacity in 3 years: Study

The whooping cough vaccine given to babies and toddlers loses much of its effectiveness after just three years. Doctors believe that could help explain a recent series of outbreaks in the U.S. among children who were fully vaccinated, a study suggests.

20 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

First effective blood-stage vaccine against malaria

Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.

15 Sep 2011

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

IUDs may protect from cervical cancer

According to the results of an international study, coil contraceptive devices might protect women against developing cervical cancer even though they don't stop the infection that commonly leads to the disease.

14 Sep 2011

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

Docs' group pushes for changes to Medicare payment setting panel

Meanwhile, other news outlets report on the challenges private practice physicians face in serving their patients and their own bottom lines, and ProPublica explores drug company payments to doctors.

9 Sep 2011

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

Flu immunization targets fall short for health workers and pregnant women

According to a new survey despite recent improvements in influenza vaccination rates among U.S. health care personnel, their rates for the 2010-2011 flu season still fell short of national health objectives.

18 Aug 2011

PAREXEL recognized as Company of the Year for the Pharmaceutical Industry

PAREXEL International Corporation, a leading global biopharmaceutical services provider, has been named Company of the Year for the Pharmaceutical Industry in The Eighth Annual International Business Awards, the only global, all-encompassing business awards program honoring great performances in business.

From Parexel 17 Aug 2011

Pharma IQ to launch Compound Management and Integrity Online event

Pharma IQ is pioneering new compound management discussion platform with launch of the first ever compound management event - Compound Management and Integrity Online event, which will take an innovative form of 11 online session over the course of 5 weeks, beginning 31st of October 2011.

11 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

U.S. District Court rules in favor of POZEN in Treximet patent litigation

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.

8 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011